Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review

Jiao Tian,1,2 Yun Zhi Chin,3 Min Hwei Ng,1 Kok Lun Pang,4 Jia Xian Law1 1Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2Department of Clinical Medicine, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People’s Republic of China; 3Division of Applied Biomedical Science and Biotechnology, School of Health Science, IMU University, Kuala Lumpur, Malaysia; 4Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, MalaysiaCorrespondence: Jia Xian Law, Email [email protected]: Breast cancer is the most prevalent malignancy among women, with triple-negative breast cancer (TNBC) being the most aggressive subtype. The lack of standard targeted therapies necessitates reliance on chemotherapy, which often suffers from poor targeting and significant off-target toxicity. This systematic review evaluates the therapeutic potential of drug delivery systems based on extracellular vesicles (EVs) for TNBC using 17 studies from 2020 to 2024 published in Scopus, PubMed, and Web of Science. The review discusses the diverse therapeutic cargos delivered by EVs, including chemotherapeutic agents and nucleic acids, while emphasizing the need for standardized protocols to facilitate EV isolation and characterization. Key findings provide both in vitro and in vivo evidence of the efficacy of EV-based therapies against TNBC cell lines and animal models, alongside insights into engineering strategies that enhance targeting specificity. Despite the promising findings, challenges remain in clinical translation, such as technical limitations and inconsistent reporting. The results underscore the potential of EVs to revolutionize TNBC treatment strategies, paving the way for more effective therapeutic options.Keywords: exosome, breast cancer, drug delivery system, precision medicine, chemotherapy

Authors

Institutions

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2026-01-01
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review

Pang KL, Chin Y.Z., Ng MH, Law JX et al.
SHILAP Revista de lepidopterología
Extracellular vesicles in disease
article

Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review

Pang KL, Chin Y.Z., Ng MH, Law JX, Tian J
article en

Abstract

Jiao Tian,1,2 Yun Zhi Chin,3 Min Hwei Ng,1 Kok Lun Pang,4 Jia Xian Law1 1Department of Tissue Engineering and Regenerative Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia; 2Department of Clinical Medicine, Zunyi Medical and Pharmaceutical College, Zunyi, Guizhou, People’s Republic of China; 3Division of Applied Biomedical Science and Biotechnology, School of Health Science, IMU University, Kuala Lumpur, Malaysia; 4Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Subang Jaya, Selangor, MalaysiaCorrespondence: Jia Xian Law, Email [email protected]: Breast cancer is the most prevalent malignancy among women, with triple-negative breast cancer (TNBC) being the most aggressive subtype. The lack of standard targeted therapies necessitates reliance on chemotherapy, which often suffers from poor targeting and significant off-target toxicity. This systematic review evaluates the therapeutic potential of drug delivery systems based on extracellular vesicles (EVs) for TNBC using 17 studies from 2020 to 2024 published in Scopus, PubMed, and Web of Science. The review discusses the diverse therapeutic cargos delivered by EVs, including chemotherapeutic agents and nucleic acids, while emphasizing the need for standardized protocols to facilitate EV isolation and characterization. Key findings provide both in vitro and in vivo evidence of the efficacy of EV-based therapies against TNBC cell lines and animal models, alongside insights into engineering strategies that enhance targeting specificity. Despite the promising findings, challenges remain in clinical translation, such as technical limitations and inconsistent reporting. The results underscore the potential of EVs to revolutionize TNBC treatment strategies, paving the way for more effective therapeutic options.Keywords: exosome, breast cancer, drug delivery system, precision medicine, chemotherapy

SHILAP Revista de lepidopterología
Tissue Regeneration Systems (United States) (US), Biotechnology Research Center (IR), Regenerative Medicine Institute (MX)
Good health and well-being
Openalex Percentile: Top 92%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review — Pang KL, Chin Y.Z., et al. · SHILAP Revista de lepidopterología (2026) | TGRS Research Map | TGRS